These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18211624)

  • 1. Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase.
    Sonmez M; Ovali E; Omay SB
    J Clin Pharm Ther; 2008 Feb; 33(1):91-2. PubMed ID: 18211624
    [No Abstract]   [Full Text] [Related]  

  • 2. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
    le Coutre P; Ottmann OG; Giles F; Kim DW; Cortes J; Gattermann N; Apperley JF; Larson RA; Abruzzese E; O'Brien SG; Kuliczkowski K; Hochhaus A; Mahon FX; Saglio G; Gobbi M; Kwong YL; Baccarani M; Hughes T; Martinelli G; Radich JP; Zheng M; Shou Y; Kantarjian H
    Blood; 2008 Feb; 111(4):1834-9. PubMed ID: 18048643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
    Al-Kali A; Farooq S; Tfayli A
    J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour lysis syndrome with acute renal failure during imatinib therapy.
    Ali R; Ozkalemkas F; Ozkan A; Ozcelik T; Ozkocaman V; Akdag I; Ozan U; Tunali A
    Leuk Res; 2007 Apr; 31(4):573-4. PubMed ID: 16782190
    [No Abstract]   [Full Text] [Related]  

  • 5. G-CSF for imatinib-induced neutropenia.
    Heim D; Ebnöther M; Meyer-Monard S; Tsakiris D; Linn M; Tichelli A; Gratwohl A
    Leukemia; 2003 Apr; 17(4):805-7. PubMed ID: 12682643
    [No Abstract]   [Full Text] [Related]  

  • 6. Catastrophic tumour lysis syndrome following single dose of imatinib.
    Keane C; Henden A; Bird R
    Eur J Haematol; 2009 Mar; 82(3):244-5. PubMed ID: 19067739
    [No Abstract]   [Full Text] [Related]  

  • 7. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase.
    Vora A; Bhutani M; Sharma A; Raina V
    Ann Oncol; 2002 Nov; 13(11):1833-4. PubMed ID: 12419759
    [No Abstract]   [Full Text] [Related]  

  • 8. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
    le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
    Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib.
    Breccia M; Muscaritoli M; Cannella L; Stefanizzi C; Frustaci A; Alimena G
    Leuk Res; 2008 Oct; 32(10):1626-8. PubMed ID: 18321570
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
    Chang H; Shih LY
    Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor lysis syndrome soon after treatment with hydroxyurea followed by nilotinib in two patients with chronic-phase chronic myelogenous leukemia.
    Hua J; Iwaki Y; Inoue M; Hagihara M
    Int J Hematol; 2013 Aug; 98(2):243-6. PubMed ID: 23649869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia.
    van Deventer HW; Hall MD; Orlowski RZ; Mitchell BS; Berkowitz LR; Hogan C; Dunphy CH; Koehler J; Shea TC
    Am J Hematol; 2002 Nov; 71(3):184-90. PubMed ID: 12410573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Dann EJ; Fineman R; Rowe JM
    J Clin Oncol; 2002 Jan; 20(1):354-5. PubMed ID: 11773197
    [No Abstract]   [Full Text] [Related]  

  • 14. Is there any protective effect on organs upon higher uric acid level in tumor lysis syndrome?
    Basturk A; Hacibekiroglu T; Akinci S; Dilek I; Atalay HV
    Ren Fail; 2011; 33(4):465. PubMed ID: 21529279
    [No Abstract]   [Full Text] [Related]  

  • 15. Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and a Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML).
    Patchenko P; Klepfish A; Trakhtenbrot L; Rothman R; Rachmilewitz EA
    Am J Hematol; 2004 Dec; 77(4):420. PubMed ID: 15558793
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of dasatinib in accelerated-phase chronic myeloid leukemia with p190 BCR-ABL1 and a second Philadelphia chromosome.
    Rabenau KE; Dolan M; Yohe S; Ustun C
    Cancer Genet; 2014 Mar; 207(3):109-10. PubMed ID: 24703333
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib.
    Menzel H; von Bubnoff N; Hochhaus A; Haferlach C; Peschel C; Duyster J
    Bone Marrow Transplant; 2007 Jul; 40(1):83-4. PubMed ID: 17450179
    [No Abstract]   [Full Text] [Related]  

  • 18. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
    Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
    Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia.
    Zakrzewski D; Seferynska I; Warzocha K; Hryniewiecki T
    Int J Hematol; 2012 Jul; 96(1):132-5. PubMed ID: 22639052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.